-
1
-
-
84872091789
-
Heart disease and stroke statistics - 2013 update: a report from the American Heart Association
-
PID: 2323983
-
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6.
-
(2013)
Circulation
, vol.127
, Issue.1
, pp. e6
-
-
Go, A.S.1
Mozaffarian, D.2
Roger, V.L.3
Benjamin, E.J.4
Berry, J.D.5
Borden, W.B.6
-
2
-
-
34547590901
-
Metabolic mechanisms in heart failure
-
COI: 1:CAS:528:DC%2BD2sXnslKksLs%3D, PID: 1764659
-
Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116(4):434–48.
-
(2007)
Circulation
, vol.116
, Issue.4
, pp. 434-448
-
-
Ashrafian, H.1
Frenneaux, M.P.2
Opie, L.H.3
-
3
-
-
77049132699
-
The metabolism of the human heart in vivo
-
COI: 1:CAS:528:DyaG2cXhvFWlsA%3D%3D, PID: 1308514
-
Bing RJ. The metabolism of the human heart in vivo. J Mt Sinai Hosp N Y. 1953;20(2):100–17.
-
(1953)
J Mt Sinai Hosp N Y
, vol.20
, Issue.2
, pp. 100-117
-
-
Bing, R.J.1
-
4
-
-
0141917504
-
Prognostic benefits of heart rate reduction in cardiovascular disease
-
Ferrari R. Prognostic benefits of heart rate reduction in cardiovascular disease. Eur Heart J Suppl. 2003;5:G10–4.
-
(2003)
Eur Heart J Suppl
, vol.5
, pp. G10-G14
-
-
Ferrari, R.1
-
5
-
-
3342967512
-
Is the failing heart energy starved? on using chemical energy to support cardiac function
-
COI: 1:CAS:528:DC%2BD2cXls1Gqtbw%3D, PID: 1527186
-
Ingwall JS, Weiss RG. Is the failing heart energy starved? on using chemical energy to support cardiac function. Circ Res. 2004;95(2):135–45.
-
(2004)
Circ Res
, vol.95
, Issue.2
, pp. 135-145
-
-
Ingwall, J.S.1
Weiss, R.G.2
-
6
-
-
33947239659
-
The failing heart—an engine out of fuel
-
PID: 1736099
-
Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356(11):1140–51.
-
(2007)
N Engl J Med
, vol.356
, Issue.11
, pp. 1140-1151
-
-
Neubauer, S.1
-
7
-
-
21244492310
-
Myocardial substrate metabolism in the normal and failing heart
-
COI: 1:CAS:528:DC%2BD2MXmsFylsr0%3D, PID: 1598780
-
Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–129.
-
(2005)
Physiol Rev
, vol.85
, Issue.3
, pp. 1093-1129
-
-
Stanley, W.C.1
Recchia, F.A.2
Lopaschuk, G.D.3
-
8
-
-
0036285606
-
Energy metabolism in the normal and failing heart: potential for therapeutic interventions
-
COI: 1:CAS:528:DC%2BD38XkvVWqtbc%3D, PID: 1198863
-
Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7(2):115–30.
-
(2002)
Heart Fail Rev
, vol.7
, Issue.2
, pp. 115-130
-
-
Stanley, W.C.1
Chandler, M.P.2
-
9
-
-
0035136262
-
An evaluation of myocardial fatty acid and glucose uptake using PET with [18 F]fluoro-6-thia-heptadecanoic acid and [18 F]FDG in patients with congestive heart failure
-
COI: 1:CAS:528:DC%2BD3MXhtF2nsbY%3D, PID: 1119798
-
Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18 F]fluoro-6-thia-heptadecanoic acid and [18 F]FDG in patients with congestive heart failure. J Nucl Med. 2001;42(1):55–62.
-
(2001)
J Nucl Med
, vol.42
, Issue.1
, pp. 55-62
-
-
Taylor, M.1
Wallhaus, T.R.2
Degrado, T.R.3
Russell, D.C.4
Stanko, P.5
Nickles, R.J.6
-
10
-
-
0028144326
-
Total-body and myocardial substrate oxidation in congestive heart failure
-
COI: 1:STN:280:DyaK2c7ms1KnsQ%3D%3D, PID: 812129
-
Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metab Clin Exp. 1994;43(2):174–9.
-
(1994)
Metab Clin Exp
, vol.43
, Issue.2
, pp. 174-179
-
-
Paolisso, G.1
Gambardella, A.2
Galzerano, D.3
D'Amore, A.4
Rubino, P.5
Verza, M.6
-
11
-
-
3342886026
-
The incidence of congestive heart failure in type 2 diabetes: an update
-
PID: 1527741
-
Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84.
-
(2004)
Diabetes Care
, vol.27
, Issue.8
, pp. 1879-1884
-
-
Nichols, G.A.1
Gullion, C.M.2
Koro, C.E.3
Ephross, S.A.4
Brown, J.B.5
-
12
-
-
0030751957
-
Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure
-
COI: 1:CAS:528:DyaK2sXlsFWrsbc%3D, PID: 924752
-
Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30(2):527–32.
-
(1997)
J Am Coll Cardiol
, vol.30
, Issue.2
, pp. 527-532
-
-
Swan, J.W.1
Anker, S.D.2
Walton, C.3
Godsland, I.F.4
Clark, A.L.5
Leyva, F.6
-
13
-
-
77956190021
-
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
-
COI: 1:CAS:528:DC%2BC3cXhtVymtbbL, PID: 2079760
-
Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, et al. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail. 2010;16(9):761–8.
-
(2010)
J Card Fail
, vol.16
, Issue.9
, pp. 761-768
-
-
Mamas, M.A.1
Deaton, C.2
Rutter, M.K.3
Yuille, M.4
Williams, S.G.5
Ray, S.G.6
-
14
-
-
0034095332
-
Myocardial substrate metabolism influences left ventricular energetics in vivo
-
COI: 1:CAS:528:DC%2BD3cXislSksrs%3D, PID: 1074973
-
Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278(4):H1345–51.
-
(2000)
Am J Physiol Heart Circ Physiol
, vol.278
, Issue.4
, pp. H1345-H1351
-
-
Korvald, C.1
Elvenes, O.P.2
Myrmel, T.3
-
15
-
-
18344394762
-
Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy
-
COI: 1:CAS:528:DC%2BD38XhslWgu70%3D, PID: 1195904
-
Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, et al. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail. 2002;4(2):181–4.
-
(2002)
Eur J Heart Fail
, vol.4
, Issue.2
, pp. 181-184
-
-
Cottin, Y.1
Lhuillier, I.2
Gilson, L.3
Zeller, M.4
Bonnet, C.5
Toulouse, C.6
-
16
-
-
54549095054
-
Effect of glucose-insulin-potassium in severe acute heart failure after brain death
-
COI: 1:CAS:528:DC%2BD1cXhtFCksbrJ, PID: 1876609
-
Nicolas-Robin A, Amour J, Ibanez-Esteve C, Coriat P, Riou B, Langeron O. Effect of glucose-insulin-potassium in severe acute heart failure after brain death. Crit Care Med. 2008;36(10):2740–5.
-
(2008)
Crit Care Med
, vol.36
, Issue.10
, pp. 2740-2745
-
-
Nicolas-Robin, A.1
Amour, J.2
Ibanez-Esteve, C.3
Coriat, P.4
Riou, B.5
Langeron, O.6
-
17
-
-
77954296979
-
A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction
-
PID: 2063185
-
Mamas A, Mamas LNFF-O. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. 2010;15(2):e20.
-
(2010)
Exp Clin Cardiol
, vol.15
, Issue.2
, pp. e20
-
-
Mamas, A.1
Mamas, L.N.F.F.-O.2
-
18
-
-
0342460492
-
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
-
COI: 1:STN:280:DyaK2szos1eksA%3D%3D, PID: 924422
-
Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96(2):526–34.
-
(1997)
Circulation
, vol.96
, Issue.2
, pp. 526-534
-
-
Anker, S.D.1
Chua, T.P.2
Ponikowski, P.3
Harrington, D.4
Swan, J.W.5
Kox, W.J.6
-
19
-
-
84878753499
-
Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives
-
PID: 2364334
-
Ahrén B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39(3):195–201.
-
(2013)
Diabetes Metab
, vol.39
, Issue.3
, pp. 195-201
-
-
Ahrén, B.1
-
20
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
COI: 1:CAS:528:DC%2BD2sXmsVynsrY%3D, PID: 1749850
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.
-
(2007)
Gastroenterology
, vol.132
, Issue.6
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
21
-
-
84898964381
-
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
-
COI: 1:CAS:528:DC%2BC2cXmslyjt74%3D, PID: 2449929
-
Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67.
-
(2014)
Int J Clin Pract
, vol.68
, Issue.5
, pp. 557-567
-
-
Brunton, S.1
-
22
-
-
84876063836
-
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study
-
COI: 1:CAS:528:DC%2BC3sXmt1ektr0%3
-
Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Int Med. 2013;173(7):534–9.
-
(2013)
JAMA Int Med
, vol.173
, Issue.7
, pp. 534-539
-
-
Singh, S.1
Chang, H.-Y.2
Richards, T.M.3
Weiner, J.P.4
Clark, J.M.5
Segal, J.B.6
-
23
-
-
33646795007
-
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
-
COI: 1:CAS:528:DC%2BD28Xlt1eqtL8%3D, PID: 1648912
-
Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317(3):1106–13.
-
(2006)
J Pharmacol Exp Ther
, vol.317
, Issue.3
, pp. 1106-1113
-
-
Zhao, T.1
Parikh, P.2
Bhashyam, S.3
Bolukoglu, H.4
Poornima, I.5
Shen, Y.-T.6
-
24
-
-
77955480007
-
Glucagon-like peptide-1 increases myocardial glucose uptake via p38 MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy
-
Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38 MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ: Heart Fail. 2010;3(4):512–21.
-
(2010)
Circ: Heart Fail
, vol.3
, Issue.4
, pp. 512-521
-
-
Bhashyam, S.1
Fields, A.V.2
Patterson, B.3
Testani, J.M.4
Chen, L.5
Shen, Y.T.6
-
25
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
COI: 1:CAS:528:DC%2BD2MXhtVWju7k%3D, PID: 1561602
-
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54(1):146–51.
-
(2005)
Diabetes
, vol.54
, Issue.1
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
26
-
-
0037629509
-
Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
-
COI: 1:CAS:528:DC%2BD3sXltF2ms78%3D, PID: 1286020
-
Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G, et al. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24(4):569–78.
-
(2003)
Peptides
, vol.24
, Issue.4
, pp. 569-578
-
-
Kavianipour, M.1
Ehlers, M.R.2
Malmberg, K.3
Ronquist, G.4
Ryden, L.5
Wikström, G.6
-
27
-
-
64649102619
-
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
-
COI: 1:CAS:528:DC%2BD1MXktleiu7o%3D, PID: 1915120
-
Noyan-Ashraf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–83.
-
(2009)
Diabetes
, vol.58
, Issue.4
, pp. 975-983
-
-
Noyan-Ashraf, M.H.1
Momen, M.A.2
Ban, K.3
Sadi, A.-M.4
Zhou, Y.-Q.5
Riazi, A.M.6
-
28
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
COI: 1:CAS:528:DC%2BD1MXhsFOgtL4%3D, PID: 1919560
-
Timmers L, Henriques JPS, de Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53(6):501–10.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.6
, pp. 501-510
-
-
Timmers, L.1
Henriques, J.P.S.2
de Kleijn, D.P.V.3
DeVries, J.H.4
Kemperman, H.5
Steendijk, P.6
-
29
-
-
11844269899
-
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines
-
COI: 1:CAS:528:DC%2BD2MXhtVWmtbY%3D, PID: 1535621
-
Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen Y-T, Elahi D, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312(1):303–8.
-
(2005)
J Pharmacol Exp Ther
, vol.312
, Issue.1
, pp. 303-308
-
-
Nikolaidis, L.A.1
Doverspike, A.2
Hentosz, T.3
Zourelias, L.4
Shen, Y.-T.5
Elahi, D.6
-
30
-
-
84879120827
-
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
-
PID: 2228544
-
Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167(2):451–7.
-
(2013)
Int J Cardiol
, vol.167
, Issue.2
, pp. 451-457
-
-
Chinda, K.1
Palee, S.2
Surinkaew, S.3
Phornphutkul, M.4
Chattipakorn, S.5
Chattipakorn, N.6
-
31
-
-
80053358548
-
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
-
COI: 1:CAS:528:DC%2BC3MXhs1Wjtb7I, PID: 2195556
-
Yin M, Silljé HHW, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10:85.
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 85
-
-
Yin, M.1
Silljé, H.H.W.2
Meissner, M.3
van Gilst, W.H.4
de Boer, R.A.5
-
32
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
COI: 1:CAS:528:DC%2BD2cXhsFeisbY%3D, PID: 1498100
-
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–5.
-
(2004)
Circulation
, vol.109
, Issue.8
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
-
33
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
COI: 1:CAS:528:DC%2BC3MXpsVGksb8%3
-
Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NEJ, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ: Cardiovasc Interv. 2011;4(3):266–72.
-
(2011)
Circ: Cardiovasc Interv
, vol.4
, Issue.3
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
Khan, F.Z.4
O'Sullivan, M.5
West, N.E.J.6
-
34
-
-
84857111888
-
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
-
COI: 1:CAS:528:DC%2BC38XltFKls7o%3D, PID: 21561896, A randomized crossover study of 14 patients with coronary artery disease and normal LV function awaiting revascularization. Participants underwent two dobutamine stress echocardiograms, one with an infusion of GLP-1 (7–36) amide and one with normal saline starting 30 min before the stress test and continuing for 30 min into recovery. At rest the infusion of GLP-1 did not affect LVEF - 62.3 ± 5.6 % (GLP-1) vs 62.6 ± 5.9 % (control); p = 0.74 – but at peak stress myocardial performance was augmented during GLP-1 infusion – LVEF 77.0 ± 4.4 % vs 70.8 ± 5.0 %; p < 0.0001. This demonstrates an important observation that GLP-1 may improve myocardial resilience during periods of ischemic stres
-
Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408–13. A randomized crossover study of 14 patients with coronary artery disease and normal LV function awaiting revascularization. Participants underwent two dobutamine stress echocardiograms, one with an infusion of GLP-1 (7–36) amide and one with normal saline starting 30 min before the stress test and continuing for 30 min into recovery. At rest the infusion of GLP-1 did not affect LVEF - 62.3 ± 5.6 % (GLP-1) vs 62.6 ± 5.9 % (control); p = 0.74 – but at peak stress myocardial performance was augmented during GLP-1 infusion – LVEF 77.0 ± 4.4 % vs 70.8 ± 5.0 %; p < 0.0001. This demonstrates an important observation that GLP-1 may improve myocardial resilience during periods of ischemic stress.
-
(2012)
Heart
, vol.98
, Issue.5
, pp. 408-413
-
-
Read, P.A.1
Khan, F.Z.2
Dutka, D.P.3
-
35
-
-
77951934948
-
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
-
Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ: Cardiovasc Imaging. 2010;3(2):195–201.
-
(2010)
Circ: Cardiovasc Imaging
, vol.3
, Issue.2
, pp. 195-201
-
-
Read, P.A.1
Khan, F.Z.2
Heck, P.M.3
Hoole, S.P.4
Dutka, D.P.5
-
36
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
COI: 1:CAS:528:DC%2BD2cXms1OgtLw%3D, PID: 1531394
-
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955–61.
-
(2004)
Circulation
, vol.110
, Issue.8
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
-
37
-
-
58949102483
-
Chronic Glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat
-
COI: 1:CAS:528:DC%2BD1cXhtV2jsrz
-
Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic Glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ: Heart Fail. 2008;1(3):153–60.
-
(2008)
Circ: Heart Fail
, vol.1
, Issue.3
, pp. 153-160
-
-
Poornima, I.1
Brown, S.B.2
Bhashyam, S.3
Parikh, P.4
Bolukoglu, H.5
Shannon, R.P.6
-
38
-
-
79951979265
-
Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy
-
COI: 1:CAS:528:DC%2BC3MXisl2jurc%3D, PID: 2135920
-
Vyas AK, Yang K-C, Woo D, Tzekov A, Kovacs A, Jay PY, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6(2):e17178.
-
(2011)
PLoS ONE
, vol.6
, Issue.2
, pp. e17178
-
-
Vyas, A.K.1
Yang, K.-C.2
Woo, D.3
Tzekov, A.4
Kovacs, A.5
Jay, P.Y.6
-
39
-
-
78149493266
-
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
-
PID: 2108095
-
Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 2010;9(1):76.
-
(2010)
Cardiovasc Diabetol
, vol.9
, Issue.1
, pp. 76
-
-
Liu, Q.1
Anderson, C.2
Broyde, A.3
Polizzi, C.4
Fernandez, R.5
Baron, A.6
-
40
-
-
33644682164
-
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
-
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes Vasc Dis Res. 2004;1(1):40.
-
(2004)
Diabetes Vasc Dis Res
, vol.1
, Issue.1
, pp. 40
-
-
Thrainsdottir, I.1
Malmberg, K.2
Olsson, A.3
Gutniak, M.4
Ryden, L.5
-
41
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
COI: 1:CAS:528:DC%2BD28XhtlaqsrzK, PID: 1717423
-
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.
-
(2006)
J Card Fail
, vol.12
, Issue.9
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
42
-
-
77749273703
-
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
-
COI: 1:CAS:528:DC%2BC3cXjsFGnsLo%3D, PID: 20081109, A well-conducted human pilot study using a randomized double-blind crossover design to study 48 hours of GLP-1 infusion in 20 NYHA II-III subjects without diabetes. The findings were notable for no significant change in cardiac index, LVEF, diastolic function, exercise capacity, regional myocardial contractile function, or BNP with GLP-1 treatment. This study also raised concerns regarding safety in the HF population, because GLP-1 infusion increased circulating insulin levels and reduced plasma glucose levels and resulted in hypoglycemia in eight patient
-
Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol. 2010;298(3):H1096–102. A well-conducted human pilot study using a randomized double-blind crossover design to study 48 hours of GLP-1 infusion in 20 NYHA II-III subjects without diabetes. The findings were notable for no significant change in cardiac index, LVEF, diastolic function, exercise capacity, regional myocardial contractile function, or BNP with GLP-1 treatment. This study also raised concerns regarding safety in the HF population, because GLP-1 infusion increased circulating insulin levels and reduced plasma glucose levels and resulted in hypoglycemia in eight patients.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
, Issue.3
, pp. H1096-H1102
-
-
Halbirk, M.1
Nørrelund, H.2
Møller, N.3
Holst, J.J.4
Schmitz, O.5
Nielsen, R.6
-
43
-
-
28144441354
-
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
-
COI: 1:CAS:528:DC%2BD28XlslGnug%3D%3D, PID: 1602457
-
Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289(6):H2401–8.
-
(2005)
Am J Physiol Heart Circ Physiol
, vol.289
, Issue.6
, pp. H2401-H2408
-
-
Nikolaidis, L.A.1
Elahi, D.2
Shen, Y.-T.3
Shannon, R.P.4
-
44
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
-
COI: 1:CAS:528:DC%2BD1cXltFyltrY%3D, PID: 1842713
-
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–50.
-
(2008)
Circulation
, vol.117
, Issue.18
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.-S.4
Drucker, D.J.5
Husain, M.6
-
45
-
-
84862521094
-
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
-
COI: 1:CAS:528:DC%2BC38Xjs1SjsrY%3D, PID: 22246377, Another more recent randomized, double-blinded crossover trial of 20 patients gives reason for caution regarding use of intravenous exenatide in patients with diabetes and HF. Although there was a significant reduction in pulmonary capillary wedge pressure during exenatide infusion, the observed improvement in cardiac index was secondary to a marked elevation in heart rate – by 21 ± 5 (29 %) bpm after 6 hours of exenatide infusion – rather than augmentation of stroke volum
-
Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926–35. Another more recent randomized, double-blinded crossover trial of 20 patients gives reason for caution regarding use of intravenous exenatide in patients with diabetes and HF. Although there was a significant reduction in pulmonary capillary wedge pressure during exenatide infusion, the observed improvement in cardiac index was secondary to a marked elevation in heart rate – by 21 ± 5 (29 %) bpm after 6 hours of exenatide infusion – rather than augmentation of stroke volume.
-
(2012)
Diabetologia
, vol.55
, Issue.4
, pp. 926-935
-
-
Nathanson, D.1
Ullman, B.2
Löfström, U.3
Hedman, A.4
Frick, M.5
Sjöholm, A.6
-
46
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
UK Prospective Diabetes Study (UKPDS) Group1
-
47
-
-
65649106228
-
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
-
COI: 1:CAS:528:DC%2BD1MXmtleksbc%3D, PID: 1946523
-
Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.
-
(2009)
Lancet
, vol.373
, Issue.9677
, pp. 1765-1772
-
-
Ray, K.K.1
Seshasai, S.R.K.2
Wijesuriya, S.3
Sivakumaran, R.4
Nethercott, S.5
Preiss, D.6
-
48
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
COI: 1:CAS:528:DC%2BD2sXms1SisrY%3D, PID: 1751785
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.
-
(2007)
N Engl J Med
, vol.356
, Issue.24
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
49
-
-
77950903574
-
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation
-
PID: 2041304
-
Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(17):1885–94.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.17
, pp. 1885-1894
-
-
Kaul, S.1
Bolger, A.F.2
Herrington, D.3
Giugliano, R.P.4
Eckel, R.H.5
-
50
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXht1Wgt7nK, PID: 1878409
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.W.5
-
51
-
-
38549162147
-
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
-
COI: 1:CAS:528:DC%2BD1cXhvVOgtLs%3D, PID: 1805332
-
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–86.
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.1
, pp. 275-286
-
-
Klonoff, D.C.1
Buse, J.B.2
Nielsen, L.L.3
Guan, X.4
Bowlus, C.L.5
Holcombe, J.H.6
-
52
-
-
77956654077
-
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database
-
COI: 1:CAS:528:DC%2BC3cXhtFahs7jJ, PID: 2046044
-
Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–65.
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1759-1765
-
-
Horton, E.S.1
Silberman, C.2
Davis, K.L.3
Berria, R.4
-
53
-
-
77958184434
-
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition
-
COI: 1:CAS:528:DC%2BC3cXhtFahs7jO, PID: 2042421
-
Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734–7.
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1734-1737
-
-
Bunck, M.C.1
Diamant, M.2
Eliasson, B.3
Cornér, A.4
Shaginian, R.M.5
Heine, R.J.6
-
54
-
-
84873554686
-
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
-
PID: 2335566
-
Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986–6.
-
(2013)
BMJ Open
, vol.3
, Issue.1
, pp. e001986-e1986
-
-
Robinson, L.E.1
Holt, T.A.2
Rees, K.3
Randeva, H.S.4
O'Hare, J.P.5
-
55
-
-
79951702236
-
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database
-
PID: 2092999
-
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. Diabetes Care. 2010;34(1):90–5.
-
(2010)
Diabetes Care
, vol.34
, Issue.1
, pp. 90-95
-
-
Best, J.H.1
Hoogwerf, B.J.2
Herman, W.H.3
Pelletier, E.M.4
Smith, D.B.5
Wenten, M.6
-
56
-
-
84876983059
-
Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature
-
COI: 1:CAS:528:DC%2BC3sXms1GktLg%3
-
Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Rev Endocrinol Metab. 2013;8(3):247–59.
-
(2013)
Expert Rev Endocrinol Metab
, vol.8
, Issue.3
, pp. 247-259
-
-
Tibble, C.A.1
Cavaiola, T.S.2
Henry, R.R.3
-
57
-
-
84865492997
-
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC38XovVagtb4%3D, PID: 2270386
-
Patil HR, Badarin Al FJ, Shami Al HA, Bhatti SK, Lavie CJ, Bell DSH, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–33.
-
(2012)
Am J Cardiol
, vol.110
, Issue.6
, pp. 826-833
-
-
Patil, H.R.1
Badarin Al, F.J.2
Shami Al, H.A.3
Bhatti, S.K.4
Lavie, C.J.5
Bell, D.S.H.6
-
58
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3sXhsF2ksbzN, PID: 2399260
-
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
Steg, P.G.4
Davidson, J.5
Hirshberg, B.6
-
59
-
-
84879460508
-
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
-
COI: 1:CAS:528:DC%2BC3sXjvFeqt7s%3D, PID: 2257010
-
Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2013;18(2):141–8.
-
(2013)
Heart Fail Rev
, vol.18
, Issue.2
, pp. 141-148
-
-
Khan, M.A.1
Deaton, C.2
Rutter, M.K.3
Neyses, L.4
Mamas, M.A.5
|